Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08

Rhea-AI Summary

Teladoc Health (NYSE:TDOC) announced an employment inducement award effective March 1, 2026, for Daniel Conroy as Chief Growth Officer, U.S. Group Health. The grant includes 57,034 restricted stock units and 57,034 performance stock units (target), with up to 114,068 PSU shares earnable.

RSUs vest one-third at the first anniversary, then quarterly over two years; PSUs vest based on three-year financial metrics. The award was approved by the Compensation Committee under the 2023 Employment Inducement Incentive Award Plan per NYSE Rule 303A.08.

News Market Reaction – TDOC

-0.19%

1 alert

-0.19% News Effect

On the day this news was published, TDOC declined 0.19%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

RSU grant size: 57,034 shares PSU target shares: 57,034 shares PSU maximum shares: 114,068 shares +3 more

6 metrics

RSU grant size 57,034 shares Restricted stock units for new Chief Growth Officer, U.S. Group Health

PSU target shares 57,034 shares Target performance stock units tied to financial metrics

PSU maximum shares 114,068 shares Maximum earnable under performance stock unit award

Common stock par value $0.001 per share Par value of Teladoc Health common stock

RSU vesting period 3 years One-third after 1 year, remainder quarterly over 2 years

PSU performance period 3 years Shares earned over three years based on financial metrics

Market Reality Check

Price: $5.12 Vol: Volume 5.70M is below 20-...

normal vol

$5.12 Last Close

Volume Volume 5.70M is below 20-day average 7.68M (relative volume 0.74x). normal

Technical Shares at $5.10 are trading below the $7.31 200-day moving average.

Peers on Argus

TDOC fell 1.16% while key peers were mixed: GDRX -0.96%, SDGR +6.20%, OMCL +1.39...

TDOC fell 1.16% while key peers were mixed: GDRX -0.96%, SDGR +6.20%, OMCL +1.39%, PHR +3.00%, CERT +4.93%, suggesting a stock-specific backdrop around this inducement award.

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Q4/FY 2025 earnings	Neutral	+15.1%	Reported flat Q4 revenue, FY revenue decline, and improved adjusted EBITDA with outlook.
Feb 18	Board appointment	Positive	+4.7%	Added experienced financial executive Michael Smith to board and key committees.
Feb 05	Earnings date set	Neutral	+5.9%	Announced timing and access details for upcoming Q4 2025 earnings release call.
Jan 12	Product expansion	Positive	-2.8%	Launched enhanced 24/7 Care nationwide, broadening virtual urgent care capabilities.
Jan 05	Investor conference	Neutral	+9.9%	CEO scheduled to present at J.P. Morgan Healthcare Conference with webcast access.

Pattern Detected

Recent news often prompted sizable moves, with 3 of the last 5 items showing price reactions that diverged from neutral or positive operational updates.

Recent Company History

Over recent months, Teladoc Health has reported mixed fundamentals and active corporate developments. On Feb 25, 2026, Q4 2025 revenue was $642.3M and full-year revenue $2,530.0M, with a Q4 net loss of $25.1M and FY net loss of $200.3M, yet the stock rose 15.05%. A board addition on Feb 18, 2026 and an earnings-date announcement on Feb 5, 2026 also saw positive reactions. Product and conference news in January showed more mixed follow-through, underscoring that even operational updates can produce varied price responses.

Market Pulse Summary

This announcement details an equity-based inducement award for a new senior leader, including 57,034...

Analysis

This announcement details an equity-based inducement award for a new senior leader, including 57,034 restricted stock units and a target of 57,034 performance stock units, vesting over several years based on service and financial metrics. It follows a period of active governance and compensation actions documented in recent Form 4 and Form 144 filings. Investors monitoring Teladoc Health may focus on how this leadership role influences growth in U.S. Group Health and on future updates to revenue and profitability trends.

Key Terms

restricted stock units, performance stock units, par value, employment inducement award

4 terms

restricted stock units financial

"granted an award of restricted stock units covering 57,034 shares of Teladoc Health’s common"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance stock units financial

"and an award of performance stock units covering a target of 57,034 shares of Common Stock"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

par value financial

"common stock, par value $0.001 per share (“Common Stock”), and an award of performance"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

employment inducement award financial

"was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan"

An employment inducement award is a grant of company stock, options, or other equity given to a new hire as a joining bonus to encourage them to work for the company. Like a signing bonus in cash, it ties the employee’s pay to the company’s future value and often vests over time. Investors care because these awards increase outstanding shares and compensation costs, affecting per‑share value and motivating executives to meet performance goals.

AI-generated analysis. Not financial advice.

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.

Effective March 1, 2026, in connection with commencing employment as Chief Growth Officer, U.S. Group Health, Daniel Conroy was granted an award of restricted stock units covering 57,034 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and an award of performance stock units covering a target of 57,034 shares of Common Stock (for which up to 114,068 shares may be earned). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The performance stock units provide a target number of shares of Common Stock that would be earned over three years based on various financial metrics. The award was approved by the Compensation Committee of the Board of Directors of Teladoc Health and was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.

About Teladoc Health

Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.

Media:
Lou Serio
pr@teladochealth.com

FAQ

What equity did Teladoc Health (TDOC) grant Daniel Conroy on March 1, 2026?

He received 57,034 restricted stock units and a target of 57,034 performance stock units. According to the company, up to 114,068 PSU shares may be earned based on three-year financial metrics.

How do the restricted stock units for TDOC vest for Daniel Conroy?

The RSUs vest one-third on the first anniversary and then quarterly over two years. According to the company, vesting is based on continued service to Teladoc Health.

What performance period applies to the Teladoc Health (TDOC) performance stock units?

The PSUs are measured over a three-year performance period tied to financial metrics. According to the company, payout ranges from a target of 57,034 shares up to 114,068 shares based on results.

Under what plan and rule was the TDOC inducement award granted?

The award was granted under the 2023 Employment Inducement Incentive Award Plan as an inducement award under NYSE Rule 303A.08. According to the company, the Compensation Committee approved the grant.

Will the Teladoc Health (TDOC) inducement award dilute existing shareholders?

The award issues RSUs and PSUs convertible into common stock if vested, which could cause dilution if earned. According to the company, up to 171,102 total shares relate to this grant if all PSUs and RSUs convert.